Regarding immunotherapy, PD-L1 is becoming quite popular as both genetic [25] and immunohistochemical [26] marker with prognostic and/or predictive roles in renal cancer patients treated with immune checkpoint inhibitors. Here, CD274 is linked to renal carcinoma.